Background: Staphylococcus aureus (S.aureus) is one of the most common causes of community acquired and hospital acquired infections. The treatment of infections caused by S.aureusremains challenging mainly due to the emergence of drug resistant isolates especially MRSA (Methicillin-Resistant Staphylococcus aureus). Multi drug resistance is one of the most common problem encountered in MRSA and this limits the treatment options.Ceftaroline, a fifth-generation broad-spectrum cephalosporin has been approved by United States Food and Drug Administration (US FDA) for treating acute bacterial SSI caused by susceptible micro-organisms including MRSA, Community acquired respiratory tract infection, MRSA bacteremia etc. Aim: To assess the susceptibility of clinical isolates of S. aureus to ceftaroline, in a Tertiary Care Hospital, South India. Materials and Methods: This cross sectional study was conducted in the Department of Microbiology of a Tertiary Care Hospital, South India, over a period of two months from May to July 2023. Thirty non duplicate S.aureusisolates from various clinical samples were screened for methicillin resistance by disc diffusion method using cefoxitin disc, Hi-Media (30 µg) and ceftaroline susceptibility of these isolates was assessed by E-strip method (Biomerieux). The isolates were classified as ceftaroline susceptible (≤1 µg/ml), Susceptibility Dose Dependent (SDD) (2-4 µg/ml) and ceftaroline resistant (≥ 4 µg/ml) respectively as per CLSI guidelines. A descriptive analysis of the data was done and the results were presented as frequencies and percentages.Results: Out of the thirty isolates tested, 28 (93%) ofS.aureusisolates were found to be susceptible to ceftaroline, with MIC’s ranging from 0.125 to 1 μg/mL.and two were Susceptible Dose Dependent (SDD). For Eight isolates the MIC value was 0.25 μg/mL.Conclusion: Ceftaroline can be considered as an effective alternative for treatment of infections caused by MRSA as it is showing good in vitro activity.